Expert Advice and Discerning Judgement

Dan Lepanto is a Senior Managing Director at Leerink Partners and leads the Biopharma Mergers & Acquisitions team.

Prior to joining the firm in 2008, Dan spent 10 years at Cowen and Company where he executed a range of biopharma M&A transactions. Dan began his career in the Mergers & Acquisitions group at Wasserstein Perella. He has advised on a number of biopharma and health care transactions over the span of his career including the sale of Dicerna to Novo Nordisk, the sale of Dermira to Eli Lilly, the sale of NPS to Shire, the sale of Cynosure to Hologic, the sale of TKT to Shire, the sale of GelTex to Genzyme, the merger of Total Renal Care with Renal Treatment Centers and the acquisition of Vivra by Gambro.

He earned his B.S. in Finance with High Honors from Pennsylvania State University.

Dan Berenson is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2019, Dan spent the early part of his career at Centerview Partners and Guggenheim Securities where he executed multiple biopharma transactions. Dan has extensive experience advising both public and private biopharma companies on matters involving mergers and acquisitions, asset sales and licensing transactions. During his 15 years as a healthcare M&A professional, he has advised on >30 strategic transactions, including Assertio’s acquisition of Spectrum Pharmaceuticals, Rocket Pharmaceuticals’ acquisition of Renovacor, Zogenix’s sale to UCB, Dermira’s sale to Eli Lilly and Ambit’s sale to Daiichi Sankyo.

He earned an M.B.A. from Yale School of Management and a B.A. from Emory College.

Philip Boyd is a Senior Managing Director in Investment Banking at Leerink Partners, he will help lead M&A efforts across Healthcare Services and Technology as well as support clients in the Healthcare Services Providers space. Phil has advised a wide variety of clients on mergers and acquisitions, divestitures, spin-offs, recapitalizations, leveraged buyouts, takeover defense, and capital raising.

Phil joined the Firm in 2024 from Guggenheim Securities, where he spent nearly a decade in the healthcare services sector, leading efforts to execute strategic transactions involving both public and private companies. Earlier in his career, he was an associate in Citigroup’s Healthcare Investment Banking Group.

He earned his B.S. in Applied Economics and Management and his M.B.A. from Cornell University.

Michael Clifford is a Senior Managing Director in Investment Banking at Leerink Partners covering Healthcare Technology and Services and supporting the Firm’s Mergers & Acquisitions efforts.

With more than 13 years of Healthcare Investment Banking experience, he has led efforts to execute strategic transactions for a variety of public and private companies on mergers & acquisitions, equity offerings (IPOs, follow-ons and private placements), acquisition financings and debt financings. Michael joined the Firm in 2015 from Wells Fargo Securities where he worked in the Consumer and Healthcare Investment Banking Group covering Healthcare Technology and Services verticals. Prior to Wells Fargo Securities, he worked in the Transaction Services group at PwC in New York.

He holds a BSBA (cum laude) in Financial Management & Investments and Accounting from the University of Arkansas.

Grant Curry is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2024, Grant was most recently a Managing Director at Dyalco, specializing in mergers & acquisitions and activism defense. He has advised on a wide range of biopharma and health care transactions, including Bristol-Myers Squibb in its acquisition of Celgene, Bristol-Myers Squibb in its acquisition of MyoKardia, Novartis on its spin-off of Sandoz, Novartis in its acquisition of AveXis, Novartis in the divestment of its consumer healthcare joint venture interest to GSK, Amgen in its acquisition of Otezla, and Charles River Laboratories in its acquisition of Cognate. Prior to joining Dyalco in 2016 as one of its first employees, Grant was a member of the Global Healthcare Group of UBS.

He earned an M.B.A. from The University of Chicago Booth School of Business and a B.A. from Whitman College.

Aniket Kaloti is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2018, Aniket spent nearly 5 years in consulting, most recently at IQVIA, advising biopharma clients on a range of strategic projects spanning corporate finance, brand and commercial strategy, business development and M&A due diligence, and financial analysis. He has advised on a number of biopharma transactions at Leerink Partners including the sale of Decibel to Regeneron, the sale of Zogenix to UCB, and the sale of Dicerna to Novo Nordisk. Earlier in his career, Aniket advised multiple biotech and health-tech startups, including with respect to raising capital through government grants and private investors. Prior to joining the industry, he was a post-doctoral scholar in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology.

He earned his M.B.B.S. (US M.D. Equivalent) from University of Mumbai, Masters’ in Biomedical Engineering at IIT Bombay and PhD in Neuroscience at Northwestern University.

Jason Truman is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2024, Jason most recently was Senior Managing Director in the Biopharma Investment Banking Practice of Guggenheim Securities. Jason brings over 20 years of investment banking experience, where he advised a wide variety of domestic and international biopharma clients in connection with mergers and acquisitions, divestitures, spin-offs/split-offs, takeover defense, proxy contests and capital raising. Specifically, Jason has advised on strategic transactions that have involved leaders in the space including such companies as Gilead, Merck, Pfizer, Alexion, Arena Pharmaceuticals, NGM Bio, and Revolution Medicines. Prior to joining Guggenheim Securities, Jason specialized in mergers and acquisitions in the biopharma space working at firms including Credit Suisse and Morgan Stanley. 

He earned his MBA from the Darden School of Business at the University of Virginia and a BBA from the Ross School of Business at the University of Michigan.

Dan Dubin, M.D., is the Vice Chairman, Co-President, Global Co-Head of Investment Banking and Global Co-Head of Healthcare Investment Banking at Leerink Partners and sits on the Firm’s executive committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients.  In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Tom Davidson is Vice Chairman, Co- President, and Global Co-Head of Investment Banking.  He serves on the Firm’s executive committee, where he shares responsibility for shaping the long-term strategy and driving the growth of Leerink Partners. Drawing on over three decades of experience advising CEOs and boards in the biopharma sector, Tom is focused on building a world class Mergers & Acquisitions business at Leerink Partners.

Over the last decade, Tom has been one of the most active M&A advisors in the biopharma sector globally. Notable recent deals include Amgen’s $27.3 billion acquisition of Horizon Therapeutics, the largest life sciences transaction of 2022, CSL’s $11.7 billion acquisition of Vifor, the largest life sciences transaction of 2021 and the $50 billion combination of Mylan and Upjohn which closed in 2020. In addition to his recurring work with some of the largest companies in the sector, he focuses a majority of his practice on working with emerging growth biotechnology companies, including Crown Laboratories, Novavax and Protagonist Therapeutics, each during 2024.

Tom joined the Firm in 2024 from PJT Partners where he was a founding partner of the firm. He previously served as Vice Chairman and Global Co-Head of Healthcare Investment Banking at Credit Suisse, where he was a member of the Global Investment Banking Operating Committee and as a Managing Director at Merrill Lynch.

Tom graduated from Yale University, summa cum laude and Phi Beta Kappa, with a BA in Economics and received his MBA from the Wharton School of the University of Pennsylvania.  Tom is a member of the Board of Trustees of the Rye Country Day School in Rye, NY.     

Barry Blake is the Global Co-Head of Investment Banking, and Global Co-Head of Healthcare Investment Banking at Leerink Partners. In this role, he co-leads the Firm’s healthcare investment banking strategy and initiatives, with a focus on Healthcare Services & Technology. With 25 years of experience, he has built extensive relationships and has proven expertise in healthcare services, medical devices and tools/diagnostics, leveraged finance, and with financial sponsors. Leading the Healthcare Services team at Leerink Partners, he has advised on numerous transactions, including the sale of LHC Group to Optum Health, a UnitedHealth Group Company, for $6B.

Barry joined the Firm in 2021 from Guggenheim Securities where he was a Senior Managing Director focused on advising healthcare services companies. While at Guggenheim he advised on many transactions including, but not limited to, the $10B sale of Envision to KKR; the $4B sale of Kindred Healthcare to a consortium comprised of TPG, Welsh Carson and Humana; the $2.4B sale of American Medical Response to KKR and the $1B sale of Almost Family to LHC Group. Prior to this, he was the Head of Global Healthcare Mergers and Acquisitions for Citigroup. While at Citigroup he worked on many transactions including, but not limited to, the $34B acquisition of Medco by Express Scripts. He also worked in the M&A and Healthcare groups at Morgan Stanley, JP Morgan and Lehman Brothers. While at JP Morgan he advised on many transactions including, but not limited to, the $4.8B acquisition of NextRx from Wellpoint by Express Scripts.

Barry earned his Bachelor of Arts in Economics from Hendrix College, and his Masters of Business Administration with high distinction from the Amos Tuck School at Dartmouth College.

He has served as a member of the Board of Trustees for each of The Hopkins School in New Haven, CT and Hendrix College in Conway, AR.

Caroline Cameron is the Chief Operating Officer of Investment Banking at Leerink Partners.

Prior to joining the Firm in 2024, Caroline was the Chief Operating Officer at Keefe, Bruyette & Woods (KBW, A Stifel Company). Prior to her time at Keefe, Bruyette & Woods, she worked in investment banking at Edgeview Partners (acquired by Piper Jaffrey), and as a research analyst at Fox-Pitt, Kelton and Macquarie Capital.

She earned a B.A. in Psychology and Economics from Hamilton College where she graduated Phi Beta Kappa.